Curcumin-Arginine Nasal Composition for Respiratory Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for infectious diseases, particularly infectious respiratory diseases and airborne infections, face challenges due to increasing microbial resistance, low solubility, and bioavailability of curcumin, as well as difficulties in nasal delivery of high molecular weight compounds.
Innovation Solution
The combination of curcumin and arginine, administered nasally, enhances solubility, permeability, and antiviral action, with arginine acting as a precursor for nitric oxide production, thereby improving treatment efficacy for infectious diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If curcumin is administered systemically, then therapeutic action is intended, but low solubility, permeability and rapid metabolism limit its effectiveness
Solution Approach 1:
The patent uses arginine as an intermediary substance that converts to nitric oxide in the nasal cavity, which then acts as the active therapeutic agent against viruses. This mediator approach allows curcumin to be delivered effectively without requiring high systemic bioavailability, as the conversion to nitric oxide occurs locally at the site of infection.
Solution Approach 2:
The patent changes the administration route from systemic to nasal, fundamentally altering the pharmacokinetic parameters. Nasal administration bypasses hepatic metabolism and gastrointestinal degradation, allowing direct delivery of curcumin-arginine complex to the respiratory tract where it converts to active nitric oxide.
2Reliability
If high molecular weight compounds are administered nasally, then local therapeutic effect is achieved, but dispersion and absorption problems occur
Solution Approach 1:
The patent creates a composite formulation combining curcumin and arginine in a nasal spray solution. This composite approach allows the substances to work synergistically, with arginine facilitating the delivery and conversion of curcumin to nitric oxide, thereby improving dispersion and absorption despite the molecular weight constraints.
3Duration of action of moving object
If curcumin is administered orally, then systemic distribution is achieved, but concentrations are too low to have antiviral effect
Solution Approach 1:
The patent employs arginine as a local intermediary that converts to nitric oxide in the nasal cavity, creating a high-concentration source of active antiviral agent directly at the site of infection. This eliminates the need for high systemic curcumin concentrations, as the conversion occurs locally.
Solution Approach 2:
The patent transitions from systemic (bloodstream) delivery to local (nasal cavity) delivery, changing the dimensional approach from whole-body distribution to targeted local concentration. This allows achieving therapeutic levels at the site of infection without requiring high systemic concentrations.
4Speed
If nasal administration is used, then rapid absorption and elimination of hepatic metabolism is achieved, but residence times of active ingredients may be short
Solution Approach 1:
The patent ensures continuous therapeutic action by formulating curcumin-arginine complex that continuously converts to nitric oxide in the nasal cavity. The formulation maintains sustained local concentration, ensuring prolonged residence time and continuous antiviral activity rather than rapid clearance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nasal administration of curcumin and arginine provides effective antiviral, antibacterial, and anti-inflammatory effects, improving the innate immune response and reducing complications associated with infectious respiratory diseases and airborne infections.
Implementation Method 1
arginine acting as a precursor for nitric oxide production
Implementation Method 2
The nasal cavity is an easily accessible organ, covered with mucous membranes that are highly vascularized and contains numerous microvilli, providing a large surface area available for the rapid absorption of therapeutic molecules
Data Source
AI summary
The present invention relates to a pharmaceutical composition for nasal delivery comprising a co-amorphous compound of curcumin and arginine for use in the treatment of infectious respiratory diseases and airborne diseases such as the respiratory infection caused by SARS-CoV-2, influenza virus, respiratory syncytial virus and adenovirus, among others.